

Appendix

**Rosalie E. Ferner, D. Gareth R. Evans,
and Susan M. Huson**

Useful Addresses

Charities

The Neuro Foundation UK

(The working name of The Neurofibromatosis Association)
Provides support for individuals with NF1 and their families
and information about Neurofibromatosis 1 and 2
Quayside House, 38 High Street, Kingston upon Thames,
Surrey KT1 1HL
Telephone +44 (0)20 8439 1234I
Fax: +44 (0)20 8439 1200I
E-mail: info@nfauk.org
Website www.nfauk.org

Changing Faces

This charity supports people with facial, limb, or body dis-
figurement and their families.
The Squire Centre, 33-37 University Street, London, WC1E
6JN.
Telephone: 0845 4500 275 or 0207 391 9270
Fax: 0845 4500 276
Email: info@changingfaces.org.uk
Website: www.changingfaces.org.uk
Website for young people: www.iface.org.uk

Hearing Concern LINK

Supports people with hearing loss and their families and organizes rehabilitation courses

19 Hartfield Road, Eastbourne, East Sussex, BN21 2AR

Telephone: 01323 638230

Text: 01323 739998

Fax: 01323 642968

Web: www.hearingconcernlink.org

Children's Tumour Foundation USA

American Neurofibromatosis Association

Children's Tumour Foundation

95 Pine Street, 16th Floor, New York, NY 10005-4002

Telephone: (00)-1-212-344-6633

Fax: (00) 1-212-747-0004

Email info@ctf.org

Nationally commissioned Neurofibromatosis 1 centres for people with complex NF1

London (Lead Centre)

Guy's and St. Thomas' NHS Foundation Trust

Contact Professor Rosalie E Ferner, Consultant Neurologist

Department of Neurology, Guy's Hospital, Great Maze Pond,

London SE1 9RT.

Manchester

Central Manchester University Hospitals Foundation Trust

Contact Dr. Susan Huson, Consultant Clinical Geneticist,

Genetic Medicine, 6th floor, St Mary's Hospital, Oxford

Road, Manchester M13 9WL.

Nationally commissioned Neurofibromatosis 2 centres

Manchester (Lead centre)

Central Manchester University Hospitals Foundation Trust

Contact Professor Gareth Evans, Consultant Clinical

Geneticist, Genetic Medicine, 6th floor, St Mary's Hospital,

Oxford Road, Manchester M13 9WL

London

Guy's and St. Thomas' NHS Foundation Trust
 Contact Professor Rosalie E Ferner, Consultant Neurologist
 Department of Neurology, Guy's Hospital, Great Maze Pond,
 London SE1 9RT

Oxford

Oxford Radcliffe Hospitals NHS Trust
 Contact Dr Allyson Parry Consultant Neurologist or Dr
 Dorothy Halliday
 Consultant Geneticist, NF2 Office, Department of Neurology,
 West Wing, John Radcliffe Hospital, Headley Way, Headington,
 Oxford, OX3 9DU

Cambridge

Cambridge University Hospitals NHS Foundation Trust
 Contact Mr Patrick Axon Consultant Skull Base Surgeon,
 Skull Base Surgery Unit, Addenbrooke's Hospital, Hills
 Road, Cambridge, CB20QQ

Back Cover Copy

Neurofibromatoses in Clinical Practice provides a succinct, accessible guide to the neurofibromatoses including diagnosis, management protocols, and indications for referral to specialist centers. Neurocutaneous diseases are complex to diagnose and treat and many patients require specialist multidisciplinary management and surveillance. Due to multiple disease manifestations, patients can present to different clinicians without specialist expertise such as general practitioners, pediatricians, neurologists, geneticists, surgeons, and ophthalmologists.

The clinically focused format of this book will enable rapid consultation during clinics, facilitate disease pattern recognition, and indicate care pathways. The clinical quiz highlights common pitfalls in diagnosis and management and a glossary and reference section provide details for access to specialist NF clinics throughout the UK and internationally.

Written by experts in the field *Neurofibromatoses in Clinical Practice* is a practical guide for consultants in training and practice, general practitioners, and specialist nurses.

Glossary of Terms

Amyotrophy Focal wasting and weakness in NF2, particularly involving the small hand muscles or thigh and may be presenting symptom of the disease.

Auditory brainstem implant (ABI) ABI is a device that stimulates the cochlear nucleus within the brainstem. It consists of an external sound processor and an internal electrode that is in contact with the brainstem. It is inserted when the auditory nerve is absent or is not functioning after tumor surgery. It helps some people with profound deafness to appreciate environmental sound and aids lip reading.

Bevacizumab (avastin) Anti-angiogenic drug. Currently used in clinical trial and as treatment in exceptional cases to reduce growth of vestibular schwannomas in NF2.

Bilateral vestibular schwannomas Benign tumors on the eighth cranial nerve that cause hearing and balance disturbance in NF2 patients. Treatment includes surgery, stereotactic radiotherapy (small risk of malignant change), and bevacuzimab in exceptional cases. Sporadic vestibular schwannomas are unilateral and develop in middle age.

Bony dysplasia Abnormalities of bone are due to defective maintenance of bone structure in NF1 patients. Include scoliosis, pseudarthrosis, and vertebral scalloping.

Café au lait patches (also called café au lait spots) Benign skin pigmentation with smooth contours. Six café au lait patches are diagnostic of NF1, but occur in smaller number in NF2. Also seen in patients with Legius syndrome, familial café patches. In the general population 10% may have up to two café au lait patches.

Carcinoid Slow growing neuroendocrine tumor that usually occurs in the duodenum in NF1. May co-exist with pheochromocytoma.

Cardiovascular disease Includes congenital heart disease, especially pulmonary stenosis and hypertension. Associated with NF1.

Cataracts Subcapsular lens opacities. Develop in young people with NF2 and may be presenting feature. Do not usually require treatment.

Cerebrovascular disease Includes stenosis, hemorrhage, and aneurysm of cerebral arteries and occurs with increased frequency in NF1.

Chiari malformation Structural abnormality in cerebellum and brainstem that pushes the brainstem and cerebellum downward. The resulting pressure may cause outflow obstruction of cerebrospinal fluid. Chiari 1 malformation does not usually cause symptoms and is reported in NF1.

Cochlear implant This is a surgically placed electronic device that is placed into the cochlea and stimulates a functioning auditory nerve to produce a sensation of hearing in deaf persons.

Cognitive problems Commonest complication in NF1 and includes low average IQ with specific learning problems and behavioral problems.

Constitutional mismatch repair deficiency syndrome (CMMR-D) This is a recessive condition caused by bi-allelic mutations in one of four mismatch repair genes. Affected individuals have a predisposition to central nervous system, hematological, and bowel malignancy. The phenotype includes multiple café au lait patches and some cases actually have somatic NF1 mutations.

Cutaneous neurofibroma Forms on the skin in people with NF1, always benign and may be purplish in color. Isolated neurofibromas may be sporadic. Cause itching, stinging, and cosmetic problems.

Disfiguring plexiform neurofibroma Large, diffuse neurofibroma of the face, trunk, or limbs that impinges on surrounding structures or is associated with bone hypertrophy. Risks of hemorrhage and delayed wound healing are high.

Dural ectasia Is visible on magnetic resonance imaging as out-pouching of the dura (the outer covering of the spinal cord) and is asymptomatic or occasionally causes pain and neurological deficit in NF1 patients.

Ependymoma Central nervous system tumor arising from ependymal cells and frequently develops in brainstem or spinal cord (particularly upper cervical region) in NF2. Maybe indolent or cause progressive neurological deficit.

Epilepsy Seizures occur with increased frequency in NF1 and NF2, and all seizure types occur. May be associated with tumors or underlying cortical dysplasia

Facial mononeuropathy This may occur in NF2 without an underlying schwannoma and is probably due to Schwann cell proliferation.

Familial café au lait patches In this rare subtype families develop café au lait patches +/- skin fold freckling but do not develop neurofibromas as adults and have a much lower risk of complications. Two genetic causes have so far been identified, SPRED1 mutations (Legius syndrome) and the c.2970-02972 delAAT mutation in the *NF1* gene.

Freckling Benign skin pigmentation under the arms, around the neck, in the groins, diagnostic of NF1.

Gastrointestinal stromal tumor Mesenchymal tumors that may be multiple and usually found in small bowel in NF1. They cause abdominal pain, anemia, or hemorrhage.

Gliomas Arise from the glial or supporting cells of the nervous system, may occur in brain or spinal cord, but mainly involve the brainstem and cerebellum in NF1. Most are low grade but some may behave aggressively. (See also optic pathway gliomas).

Glomus tumor Benign tumor of glomus body which causes exquisite pain in nail bed and may be multiple in NF1 patients.

Legius syndrome This is a milder phenotype than NF1 with café au lait patches, freckling but no neurofibromas and with mutation in the *SPRED1* tumor suppressor gene.

Lisch nodules Benign asymptomatic raised pigmented lesions on the iris, seen on slit lamp examination and diagnostic of NF1.

Malignant peripheral nerve sheath tumor (MPNST) NF1 patients have a 10% lifetime risk of developing MPNST that may be low, intermediate, or high grade. Presentation is with persistent pain, change in texture, rapid increase in size of a lump, or neurological deficit.

Meningiomas Benign tumors that develop in the orbit, brain, and spine, and may be multiple. Characteristic of NF2 but do not occur with increased frequency in NF1.

Merlin (schwannomin) The protein product of the *NF2* gene is related to the moesin, ezrin, radixin, proteins that control growth and cellular remodeling.

Mosaic NF1 The gene mutation (alteration in the genetic message) occurs after fertilization. The proportion of the body affected by the disease is dependent on the timing of the

mutation after fertilization. The commonest form is for one body segment to show NF1 skin changes (segmental NF1).

Mosaic NF2 Mosaic NF2 presents as mild generalized NF2 or NF2 features that are localized to one area of the body (e.g., unilateral vestibular schwannomas and meningiomas).

mTOR mTOR mammalian target of rapamycin is involved in cell growth and proliferation. Rapamycin has been used in clinical trials to treat growing plexiform neurofibromas.

Multiple sclerosis Occurs with increased frequency in NF1, particularly primary progressive multiple sclerosis. The clinical manifestations may be confused with symptoms related to optic pathway gliomas or spinal plexiform neurofibromas.

Neuro-cardio-facial-cutaneous syndromes (also called Rasopathies) The collective term given to the conditions caused by mutations in the Ras-MAPK pathway which include NF1 and Legius syndrome.

Neurofibroma Benign peripheral nerve sheath tumor that occurs on or under the skin or on the spinal nerve roots or nerve plexuses. Composed of Schwann cells, fibroblasts, perineurial cells, and axons in an extracellular matrix. (See also cutaneous neurofibroma, subcutaneous neurofibroma, plexiform neurofibroma.)

Neurofibromatosis 1 An inherited neurocutaneous condition that predisposes to benign and malignant tumor formation and is caused by mutations in the *NF1* gene on chromosome 17.

Neurofibromatosis 2 A rare inherited neurocutaneous condition that is characterized by vestibular schwannomas, other benign brain and spine tumors, and cutaneous and eye signs. It is caused by mutations in the *NF2* gene on chromosome 22.

Neurofibromatosis 2 neuropathy Axonal peripheral neuropathy which may be motor and sensory and is progressive in some patients.

Neurofibromatous neuropathy (NF1) An indolent motor and sensory neuropathy in NF1. Affected individuals harbor an increased risk of malignant peripheral nerve sheath tumor.

Neurofibromin The *NF1* gene product is neurofibromin which regulates cell growth and proliferation by inactivation of p21ras and control of mammalian target of rapamycin (mTOR).

NF1 microdeletions This is the genetic mechanism that causes the disease in approximately 5% of people with NF1. In addition to the *NF1* gene the deletion, depending on size, involves a number of other neighboring genes. Microdeletions are associated with more severe clinical manifestations.

Nonossifying fibromas Cystic lesions of bone in NF1 patients that may be painful or cause pathological fracture.

Optic pathway glioma (OPG) These tumors arise from the glial cells in the central nervous system. They form anywhere on the optic pathway but are commonest in the optic nerves in NF1. Most tumors are indolent and do not need treatment, but some cause decreased vision in childhood and require chemotherapy.

Pheochromocytoma Catecholamine secreting tumor, mainly found in the adrenal medulla in NF1. It may be bilateral and is occasionally malignant. It causes hypertension and may coexist with carcinoid tumor.

Plexiform neurofibroma Benign peripheral nerve sheath tumor that grows along the length of the nerve, often involves multiple nerves, frequently causing neurological deficit, and may undergo malignant change in NF1.

Positron emission tomography (PET CT) ([¹⁸F]2-fluoro-2-deoxy-D-glucose positron emission tomography computerized tomography) is the optimum way of diagnosing malignant peripheral nerve sheath tumor. It gives qualitative and semi-quantitative evaluation of the metabolic activity of a tumor. It should only be used in NCG specialist centers for this purpose and is not useful for assessing schwannomas.

Preimplantation genetic diagnosis Available for people with NF1 and NF2. Healthy embryos are selected on the third day of fetal development.

Pseudarthrosis Causes bowing of the long bones, most commonly the tibia. Fracture occurs after trivial injury in infancy and childhood with delayed healing. The presentation may be mistaken for nonaccidental injury instead of NF1.

Renal artery stenosis Associated with hypertension in NF1 and caused by dysplasia of blood vessels or aneurysm.

Schwannoma This is a benign nerve sheath tumor composed of Schwann cells and has a capsule. May be sporadic, but multiple lesions are characteristic of NF2 or Schwannomatosis. Malignant

change is rare and PET CT does not detect malignant change in schwannomas (see PET CT). In NF2, schwannomas form on cranial, spinal, peripheral, and cutaneous nerves.

Schwannomatosis This rare condition is characterized by multiple schwannomas (but not eighth nerve schwannomas). May be familial, and the gene is tumor suppressor *INI1* (*SMARCB1*).

Scoliosis Curvature of the spine in NF1 that may be idiopathic or dystrophic and the latter may cause neurological or respiratory problems. Occasionally, it may be associated with an underlying plexiform neurofibroma.

Segmental NF1 (see mosaic NF1)

Skin schwannomas Skin schwannomas may be subcutaneous, intradermal, or plaque lesions in NF2.

Sphenoid wing dysplasia Defective formation of the skull bones diagnostic of NF1. The temporal lobe may push forward into the orbit and cause pulsating protrusion of the eye.

Spinal cord compression Spinal nerve root neurofibromas may cause pressure on the nerve roots and spinal cord. Many do not need intervention despite the neuroradiological appearances of cord compression, but some cause neurological deficit, particularly in the upper cervical spine, and require surgery.

Spinal neurofibromatosis Hereditary spinal neurofibromatosis is a rare form of NF1 and the characteristic features are multiple spinal neurofibromas with or without peripheral nerve involvement and relatively few café au lait patches.

Statins Lovastatin reverses ras activity, and statin drugs are being used in clinical trial to treat learning problems in children with NF1.

Subcutaneous neurofibroma This firm, discrete neurofibroma under the skin causes pain and neurological symptoms and may become cancerous.

T2 hyperintensities on brain MRI These are asymptomatic lesions that are found especially in the basal ganglia, cerebellum, and brainstem in people with NF1. They do not cause neurological deficit and disappear with age.

Vertebral scalloping This is pronounced curvature of the dorsal part of the vertebral body and is seen on MRI in NF1 patients and is asymptomatic.

Xanthoanguloma Yellowish nodule occurring transiently on the head, limbs, and trunk in NF1 children.

Index

A

- Absence seizures, 145, 147
- Amyotrophy, 141, 143, 152
- Auditory brainstem implant (ABI), 135, 136, 141, 142, 146, 152

B

- Behavioral problems, NF1, 24–25
- Bony dysplasia, 115, 152

C

- Café au lait (CAL) patches, 152
 - features of, 78–80
 - NF1, 4–5, 112
 - NF2, 55
- Campbell de Morgan spots, 5, 7
- Carcinoid tumor, 37
- Cardiovascular disease, 35–37
- Cataracts, 152
 - NF1, 55–57
- Cerebello-pontine (CP) angle tumors, 121
- Cerebrovascular disease, 33–34
- Chiari malformation, 31, 152
- Clawing, intrinsic hand muscles, 144, 147
- Cognitive impairment, NF1, 24–25
- Constitutional mismatch repair deficiency syndrome (CMMR-D), 153
- Contraceptive pills and neurofibroma, 145

- Cutaneous neurofibromas,
 - 142, 144
 - definition, 153
 - NF1, 13–14
 - psychological impact of, 131–133

D

- Diffuse plexiform neurofibroma, 142, 145, 147
- Dural ectasia, 32, 153

E

- Ependymoma, 153
- Epilepsy, 32–33, 153

F

- Freckling, 5, 6, 80–81, 154

G

- Gastrointestinal disease, 37
- Gastrointestinal stromal tumors (GIST), 37, 154
- Genetic and prenatal counseling
 - NF1
 - accuracy and cost of, 39
 - prenatal testing, 38
 - segmental NF1 patients, 39
 - NF2
 - mode of inheritance, 63
 - predictive testing, 65
 - risk to family members, 63–65
- Glomus tumors, 5–6, 141, 146, 154

H

Heart disease, 36

L

Legius syndrome, 96–100, 154
LEOPARD syndrome, 105–106
Lisch nodules, 34, 154

M

Macrocephaly, 30–31
Malignant peripheral nerve sheath tumor (MPNST), 19
 diagnosis, 21
 occurrence, 20
 treatment, 21–23
McCune Albright syndrome, 112–113
Melanocytic nevi, 113
Merlin, 58, 154
Microdeletion syndrome, 87–90
Mononeuropathy, 58
Mosaicism
 NF1, 2–4
 NF2, 49–50
Multiple lipomatosis, 114
Multiple sclerosis, 33, 155

N

Nationally Commissioned Complex
 NF1 service, 41–42
Neurofibromatoses
 clinical assessment, 75
 disease features and age
 of development, 71–73
 examination of, 77
 eye features, 83
 family history, 77
 NF1/NF2 overlap, 83–84
 NF1 subtypes (*see* Neurofibromatosis 1 (NF1))
 NF2 subtypes
 cerebello-pontine (CP) angle tumors, 121
 multiple meningiomas, 121
 schwannomatosis, 119–121
 past medical history, 75–76

peripheral nerve tumors
 neurofibromas *vs.* schwannomas, 81–82
 NF2 plaques, 82
pigmentary changes
 café au lait spots, 78–80
 skin fold freckling, 80–81
 radiology/histology review, 77–78
Neurofibromatosis 1 (NF1). *See also* Neurofibromatoses
 assessment and follow-up
 adults, 40–41
 children, 39–40
 young people 16–25 years, 40
 bone abnormalities
 mineral density reduction, 10
 pseudarthrosis, 8–9
 short stature, 9
 brain tumors, 25–27
 CAL spots and disorders, 96, 112–113
 carcinoid tumors, 37
 cardiovascular disease, 35–37
 cerebrovascular disease, 33–34
 CFC syndrome, 106–107
 clinical phenotype, 90–93
 cognitive impairment, 24–25
 congenital melanocytic nevi, 113
 diagnostic criteria, 1–2
 epidemiology, 2
 epilepsy, 32–33
 exon 17 3-bp infragenic deletion, 100
 gastrointestinal disease, 37
 genetic diagnosis and counseling, 38–39
 genetics of, 3–4
 genetic testing indications, 118
 gliomas, 25–27
 glomus bodies, 5–6
 Legius syndrome, 96–100
 LEOPARD syndrome, 105–106
 microdeletion syndrome, 87–90
 mismatch repair deficiency, 108–110
 mosaicism, 2–4, 87

- multiple lipomatosis, 114
 - multiple sclerosis, 33
 - Nationally Commissioned
 - Complex NF1 service, 41–42
 - and NCFC syndromes, 101–105
 - nervous system malformations, 30–32
 - neurofibromas
 - cutaneous form, 13–14
 - peripheral nerve sheath tumor, malignant, 19–23
 - plexiform, 16–21
 - spinal form, 16–18
 - subcutaneous form, 14–16
 - neurological complications, 11–12
 - neuropathy, 23–24
 - non-ossifying neurofibromas, 11
 - Noonan syndrome, 105
 - optic pathway gliomas, 27–30, 34
 - pigmentary dysplasia, 111–112
 - pitfalls of, 115–118
 - pregnancy, 37–38
 - Proteus syndrome, 114–115
 - psychological impact
 - cutaneous and subcutaneous neurofibromas, 131–133
 - disfigurement, 131
 - education, 133
 - expert clinician's requirement, 130–131
 - facial plexiform neurofibromas, 131
 - unpredictability, disease complications, 129–130
 - scoliosis, 10–11
 - segmental/localized form, 85–86
 - skin manifestations, 4–7
 - spinal form, 93–95
 - steatocystoma multiplex, 114
 - urticaria pigmentosa, 113
 - vertebral scalloping, 11
 - Watson syndrome, 95–96
 - xanthogranulomas, 5, 7
-
- Neurofibromatosis 2 (NF2)
 - cerebello-pontine (CP) angle tumors, 121
 - clinical manifestations
 - classification, 50–52
 - cutaneous features, 54–56
 - ophthalmic features, 54
 - polio-like illness, 53
 - schwannomas, 50–54
 - complications, 65–66
 - diagnostic criteria, 48–49
 - differential diagnosis, 59–60
 - epidemiology, 49
 - genetic and prenatal counseling, 63–65
 - genetics, 58–59
 - management methods
 - hearing rehabilitation, 62
 - radiotherapy, 61–62
 - surgery, 60–61
 - targeted therapy, 62–63
 - mononeuropathy, 58
 - mosaicism, 49–50
 - multiple meningiomas, 121
 - name and synonyms, 47–48
 - psychological impact
 - hearing rehabilitation, 135–136
 - neuro foundation, 137
 - patient as educator, 137–139
 - quality of life measurement, 134–135
 - specialist advisers, 136–137
 - schwannomatosis, 119–121
 - screening method
 - cataract occurrence, 55–57
 - genetic test, 57
 - MRI, 57
 - Nonossifying fibromas, 11, 156
 - Noonan syndrome, 105
-
- O**
- Optic pathway gliomas, 27
 - disease surveillance in, 29
 - indications, 30
 - risk factors, 28
 - screening method, 29

signs and symptoms, 28–29
treatment, 30
Osteoporosis, 10

P

Pheochromocytoma, 35–36, 156
Polio-like illness, 53
Pregnancy, NF1 complications in,
37–38
Preimplantation genetic diagnosis,
38, 65, 156
Proteus syndrome, 114–115
Pseudarthrosis, 8–9, 156

R

RASopathies, 101, 106, 155
Renal artery stenosis, 35
Ring chromosome syndromes, 112

S

Schimke immunoosseus dysplasia,
112
Schwannoma, 15, 53, 54, 56, 60,
81–82, 144, 156–157
Schwannomatosis, 157
diagnostic criteria, 119–120

genetic mechanisms, 120–121
NF2 differential diagnosis,
59–60

Scoliosis, 10–11, 157

Seizures, 145, 147

Short stature, NF1 bone
abnormality, 9

Sphenoid wing dysplasia, 31, 157

Spinal neurofibromatosis, 94, 142, 147

Statins, 157

Steatocystoma multiplex, 114

Sudden bilateral hearing loss, 141

U

Urticaria pigmentosa, 106, 113

V

Vertebral scalloping, 11, 157

W

Wasting, intrinsic hand muscles,
144, 147

Watson syndrome, 95–96

X

Xanthogranuloma, 5, 7, 157